Elite Pharmaceuticals (QB) Stock Price - ELTP

-0.0036 (-3.87%)
Best deals to access real time data!
Small Cap Pro
Monthly Subscription
for only
Canna Trader Pro
Monthly Subscription
for only
Small Cap Basic
Monthly Subscription
for only
VAT not included
Company Name Stock Ticker Symbol Market Type
Elite Pharmaceuticals Inc (QB) ELTP OTCMarkets Common Stock
  Price Change Change Percent Stock Price Low Price High Price Open Price Close Price Last Traded
-0.0036 -3.87% 0.0894 0.085 0.0923 0.09 0.093 16:25:09
Bid Price Ask Price Spread Spread % News
0.085 0.0945 0.0095 10.05% - -
Stock Trades Traded Volume VWAP Dollar Volume Average Volume 52 Week Range
54 565,303 $ 0.086119 $ 48,683 1,127,192 0.0333 - 0.141
Last Trade Time Type Quantity Stock Price Currency
15:48:05 500 $ 0.0894 USD

Elite Pharmaceuticals (QB) Financials

Market Cap Shares in Issue Profit/Loss Earnings Per Share (EPS) PE Ratio Float
$ 75.02M 839.19M $ -3.67M - - 793.80M
Short Interest Dividends Per Share Dividend Yield Ex-Div Date Insider B/S Insider % Owned
84.99k $ - 0.00% - -

more financials information »

Elite Pharmaceuticals (QB) News

Loading Messages....

Latest ELTP Messages

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....

No posts yet, be the first! No {{symbol}} Message Board. Create One! See More Posts on {{symbol}} Message Board See More Message Board Posts

Historical ELTP Price Data

Period † Open High Low VWAP Avg. Daily Vol Change %
1 Week0.09050.09690.0850.0904132892,461-0.0011-1.22%
1 Month0.110.110.0850.0980984937,269-0.0206-18.73%
3 Months0.0890.1150.08020.09750891,208,1760.00040.45%
6 Months0.0580.1410.0570.09560611,004,7480.031454.14%
1 Year0.0890.1410.03330.0856888841,8730.00040.45%
3 Years0.13250.24950.03330.1067496833,693-0.0431-32.53%
5 Years0.220.4430.03330.1837511,016,062-0.1306-59.36%

Elite Pharmaceuticals (QB) Description

Elite Pharmaceuticals, Inc. is a specialty pharmaceutical company which is developing a pipeline of proprietary pharmacological abuse-deterrent opioid products as well as niche generic products. Elite specializes in oral sustained and controlled release drug products which have high barriers to entry. Elite owns generic products which have been licensed to TAGI Pharma, Glenmark Pharmaceuticals, Inc., USA., and Lannett Company, Inc. Elite currently has twelve approved generic products, four generic products filed with the FDA, one approved generic products pending manufacturing site transfer, and an NDA filed for SequestOx. Elite's pipeline products include abuse-deterrent opioids which utilize the Company's patented proprietary technology and a once-daily opioid. These products include sustained release oral formulations of opioids for the treatment of chronic pain. These formulations are intended to address two major limitations of existing oral opioids: the provision of consistent relief of baseline pain levels and deterrence of potential opioid abuse. Elite operates a GMP and DEA registered facility for research, development, and manufacturing located in Northvale, NJ. Learn more at www.elitepharma.com.

Your Recent History
Gulf Keyst..
FTSE 100
UK Sterlin..
Stocks you've viewed will appear in this box, letting you easily return to quotes you've seen previously.

Register now to create your own custom streaming stock watchlist.